The Gates Foundation (GF) has awarded German biotechnology company Evotec a USD 2.5 million grant to support the development of next-generation treatment regimens for tuberculosis (TB).

Evotec said it will further characterise promising regimens using its fully integrated TB platform to accelerate the development of transformative TB treatments and significantly impact global health.

The new funding builds on an ongoing five-year partnership that has already generated preclinical data used for shorter, safer, and more effective TB drug combinations.

Chief Scientific Officer of Evotec, Dr. Cord Dohrmann, said, “We are honoured to receive this new grant from GF, which reinforces our shared commitment to advancing better treatment options for tuberculosis. Through our ongoing partnership, we have made important contributions to the identification of promising new regimens, and this grant enables us to continue that work.”

This is the second grant awarded to Evotec by the Gates Foundation focused on evaluating new and improved TB therapies.